Interaction Between Oxcarbazepine and Long-Acting Aripiprazole Leading to Relapse of Bipolar Disorder

Shehryar Khan, MD; Hayley Walton, MD

Prim Care Companion CNS Disord 2025;27(2):24cr03877

Free Access: Please Log In

This content is completely free—but you need to be logged in to read the full article. If you already have an account, please log in below. Otherwise, register for free to unlock instant access.

References (7)

Citrome L. Aripiprazole: review of its pharmacology and clinical efficacy in the management of schizophrenia and bipolar disorder. Clin Schizophr Relat Psychoses. 2006;1(1):17–29.
Mauri MC, Paletta S, Di Pace C, et al. Clinical pharmacokinetics of atypical antipsychotics: an update. Clin Pharmacokinet. 2018;57(12):1493–1528. CrossRef
Andreasen AH, Brøsen K, Damkier P. A comparative pharmacokinetic study in healthy volunteers of the effect of carbamazepine and oxcarbazepine on CYP3A4. Epilepsia. 2007;48(3):490–496.
Paton C, Ferrier IN. Lithium: pharmacology and clinical efficacy in bipolar disorder. Adv Psychopharmacol. 2010;1(2):259–269.
Spina E, de Leon J. Clinical consequences of cytochrome P450 3A4 inhibition. Clin Pharmacokinet. 2007;46(10):813–858.
Lohoff FW, Ferraro TN. Pharmacogenetic considerations in the treatment of bipolar disorder. Pharmacogenomics J. 2010;10(3):148–161.
Dean L, Kane M, Pratt VM, eds, et al. Aripiprazole therapy and CYP2D6 genotype. Medical Genetics Summaries [Internet]. National Center for Biotechnology Information (US); 2012:1–12. Accessed October 20, 2024. http://www.ncbi.nlm.nih.gov/pubmed/28520375.